AN2 Therapeutics, Inc. ANTX 深 滬
已收盤 05-08 16:00:00 美东时间
4.46
-0.140
-3.04%
華盛通- 最 高4.83
- 今 開4.59
- 成交量 24.20万股
- 最 低 4.46
- 昨 收 4.60
- 總市值 1.61亿
- 52周最高 6.9099
- 市盈率 靜 --
- 換手率 0.67%
- 52周最低 1.00
- 委 比 36.67%
- 總股本 3599.55万
- 歷史最高 23.58
- 量 比 1.12
- 振 幅 8.04%
- 歷史最低 0.87
- 每 手 1
- 風險率 1.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2
03-31 19:07
AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 16 percent decrease over losses of $(0.25) per share from
03-18 04:07
AN2 Therapeutics Stock Cools Off After 90% Rally
AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.
03-11 21:52
美股牛股 | 医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%
医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%，获诺和诺德授权销售其减肥药；QURE大涨26%，FDA疫苗负责人将离职，有分析称监管政策或转向灵活>>
03-10 16:46
AN2 Therapeutics Plans Phase 2 Trial Of Oral Epetraborole In Polycythemia Vera; Study To Begin Q3 2026 With Potential For Data Readouts As Early As Q4 And Throughout 2027
Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027AN2 to host webcast on Wednesday,
03-04 05:01
The FDA Clears Oregon Health & Science University's Investigational New Drug Application To Proceed With Investigator-Initiated Trial Of AN2 Therapeutics' Epetraborole For Mycobacterium Abscessus Lung Disease, Patient Enrollment To Start In Q1 2026
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapiesLed by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop, trial will focus on early-stage,
01-12 20:10
AN2 Therapeutics reports Q3 results
AN2 Therapeutics press release (ANTX): Q3 net loss was $9.4 million. The Company had cash, cash equivalents and investments of $65.1 million at September 30, 2025. More on AN2 Therapeutics Seeking Alp...
2025-11-13 23:20
AN2 Therapeutics Q3 EPS $(0.31) Misses $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 4.73 percent. This is a 27.91 percent increase over losses of $(0.43) per share from
2025-11-13 05:30
